Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials
JCO Precision Oncology · 2023
DOI: 10.1200/po.22.00573 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Thomas B Karasic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA.
- Department of Medicine, Division of Hematology and Oncology, Stanford Cancer Center, Palo Alto, CA.
ORCID-Profile: Thomas B Karasic, Jennifer R Eads, Lipika Goyal
Förderung
- NCI NIH HHS
Zitieren
APA
Karasic, T. B., Eads, J. R., & Goyal, L. (2023). Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials. JCO Precision Oncology. https://doi.org/10.1200/po.22.00573
Vancouver
Karasic TB, Eads JR, Goyal L. Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials. JCO Precision Oncology. 2023. doi:10.1200/po.22.00573
BibTeX
@article{Karasic2023,
author = {Karasic, Thomas B and Eads, Jennifer R and Goyal, Lipika},
title = {Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials},
journal = {JCO Precision Oncology},
year = {2023},
doi = {10.1200/po.22.00573}
}
EUVIMED